The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the Respiratory Syncytial Virus (RSV) Therapeutics Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025?
The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025, maintaining an impressive compound annual growth rate (CAGR) of 25.0%. Factors contributing to this historic growth trend include heightened awareness of the disease, breakthroughs in virology, the susceptibility of children, epidemic occurrences, and vaccine advancements.

What's the Long-Term Growth Forecast for the Respiratory Syncytial Virus (RSV) Therapeutics Market Size Through 2029?
The market size of therapeutics for the respiratory syncytial virus (RSV) is projected to see a significant surge in the upcoming years, reaching $4.59 billion in 2029 with a compound annual growth rate (CAGR) of 23.1%. The predicted expansion during the forecast period is linked to factors such as the innovation in biologic therapies, the rise of new antivirals, increased attention to the aging population, strategies for maternal immunization, and worldwide research partnerships. Key trends for this period involve advancements in monoclonal antibodies, development in nasal vaccines and their delivery methods, combination treatments, novel techniques in drug delivery, and options for treatment at home.

View the full report here:
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Respiratory Syncytial Virus (RSV) Therapeutics Market Expansion?
The surge in RSV infection cases is a key contributor to the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV is a common respiratory ailment that can trigger mild to serious respiratory infections, predominantly in newborns, young children, elderly individuals, and those with weakened immune systems. The rising occurrences of RSV infections necessitate the creation of novel treatments to fulfill the increasing demand and alleviate the intensity of RSV-linked complications. For example, in September 2023, the Centres for Disease Control and Prevention, a public health agency based in the U.S., reported a substantial hike in RSV-related hospitalization rates among children under 4 years. The figures rose from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Therefore, the escalating prevalence of RSV infection fuels the growth of the respiratory syncytial virus (RSV) therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp

What Are the Key Trends Driving Respiratory Syncytial Virus (RSV) Therapeutics Market Growth?
The trend of inventing new and more effective drugs and vaccines is burgeoning in the Respiratory Syncytial Virus (RSV) therapeutics market. The prominent corporations in the market are putting their efforts into innovating fresh drugs and vaccines to secure their stakes in the market. For example, Pfizer Inc., an American pharmaceutical manufacturing company, was granted clearance for ABRYSVO by the Food and Drug Administration, a US federal body entrusted with the safety and promotion of public health, in May 2023. The dual component RSVprefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent the lower respiratory tract diseases caused by RSV in people aged 60 or above. ABRYSVO, an unadjuvanted vaccine formulated of a pair of preF proteins that are custom-made to augment immunity against RSV A and B strains, is extensively clinically approved for being safe and effective.

How Is the Respiratory Syncytial Virus (RSV) Therapeutics Market Segmented?
The respiratory syncytial virus (RSV) therapeutics market covered in this report is segmented -

1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp

Which Companies Are Leading the Charge in Respiratory Syncytial Virus (RSV) Therapeutics Market Innovation?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd

Which Regions Are Leading the Global Respiratory Syncytial Virus (RSV) Therapeutics Market in Revenue?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12601

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.